Glucagon-like peptide-1 receptor agonists in hidradenitis suppurativa: A nationwide cohort study.

Journal of the European Academy of Dermatology and Venereology : JEADV

Incretin therapy prescription in a high cardiovascular risk population: Insights from a cardiology-based cardiometabolic program.

American journal of preventive cardiology

Comorbid Cardiovascular-Liver Disease Disparities: Current Understanding and Future Directions.

Current cardiology reports

Semaglutide for MASH cirrhosis: a new therapeutic frontier or a false dawn?

eGastroenterology

Predictors of treatment response to semaglutide for weight management.

Frontiers in endocrinology

Interactions of Glucagon-Like Peptide-1 Receptor Agonists With GLP-1R-Gs Complex: Insights From Gaussian-Accelerated Molecular Dynamics.

Proteins

Effects of semaglutide on kidney disease in type 2 diabetes: a randomized placebo-controlled trial.

Nature medicine

Cardiovascular protection beyond glucose lowering: GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonism in contemporary cardiology.

Frontiers in cardiovascular medicine

Sat down with @RyanJAyala on the Alchemist's Library Podcast. Enjoyed it! Here's the video. 0:00 Intro and why lean beats bulking 1:15 Lean is law: looks maxing and the movie star physique 3:26 Why Greg is pro GLP-1s (food noise and calorie friction) 5:32 How to use GLP-1s https://t.co/FEgsWxxo30

If you are seeing BPC-157 promoted for injury recovery, here is the reality check: The first American placebo-controlled trial of BPC-157 injections has not enrolled a single patient. Despite posts saying the @UArkansas "just launched” the study, the registry says recruiting https://t.co/OZ5TxW8IJE

Semaglutide reset expectations. Tirzepatide reset them again. And a quieter race has been running behind both. The pattern is simple once you see it: each new molecule adds a receptor, and each added receptor lifts the ceiling. Semaglutide hits one and established roughly 15%

Peptides get a lot of attention. But here's a better way to think about them: Semaglutide → muscle preservation Tirzepatide → GI health Retatrutide → metabolic research BPC-157 → human evidence GHK-Cu → collagen biology CJC-1295 → sleep + GH The interesting part isn't hy https://t.co/G89O1sbWnO

As a sports medicine doctor, here’s what I want you to know about peptides Patients often ask me whether these compounds can help improve their physical health and increase longevity. This is what I tell them. Should I be taking peptides to support my health and fitness goals? https://t.co/2nWiF8Ijdm

🚨 BIG NEWS FOR PEPTIDES. The FDA just made a major regulatory move involving 17 peptide drugs — including semaglutide, tirzepatide, liraglutide and glucagon. 🧬 The agency published new guidance designed to advance the development and assessment of generic peptide medicines.

Your favorite influencer's peptide stack just got a Harvard reality check. Harvard Chan School draws the line: semaglutide is tested, FDA approved, prescription only. BPC 157, TB 500, MOTS c, CJC 1295, ipamorelin? Little to no clinical testing, no FDA approval, sold through gray https://t.co/Kdp2XrwuFW

Peptide and health news you might have missed this week: - Greenwich Rx recalled its compounded glutathione injection nationwide over possible high endotoxin levels, per an FDA notice on 1 Oct. - The Philippine FDA warned the public against unregistered retatrutide, NAD+ and